Alzheimer’s Disease Treatment: Canadian-Led Innovation…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD)…
Tagged with Alzheimer's
Gunilla Osswald – CEO, BioArctic, Sweden
BioArctic is a Swedish biopharma company with the vision to become a world-leader in the research and development of disease-modifying treatments for…
Sweden’s BioArctic: A Potential Paradigm Shift in Alzheimer’s…
Swedish biotech BioArctic, in collaboration with Japanese firm Eisai, has seen positive Phase IIb results for its BAN2401 antibody – potentially the…
Alzheimer’s Disease R&D Expenditure Snapshot 2019
Alzheimer’s drugs represent a high-risk, high-reward proposition for global pharma. As David H. Crean recently wrote for PharmaBoardroom,…
The Ongoing Battle to Crack the Alzheimer’s Treatment Dilemma
David H. Crean highlights R&D efforts and ongoing investments in Alzheimer’s disease treatments as we enter the month of June, brain awareness…
Is CNS the Next Oncology?
Cerecin’s Charles Stacey looks at the large unmet medical need in diseases of the central nervous system (CNS), the looming socioeconomic burden…
Martin Dubuc – General Manager, Biogen France
Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the…
Joël Jaouen – President, France Alzheimer
Joël Jaouen, president of France Alzheimer, provides important insights into the role and objectives of the patient association. He explains why…
Charles Stacey – President & CEO, Cerecin
Dr Charles Stacey, president and CEO of Brain Health company Cerecin, formerly Accera, discusses the rebrand, new investment, the company’s…
UK Charities: The Funding Giants of Medical Research
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6…
Biogen: The Only Hope for Alzheimer’s?
After completing Phase II of clinical trials, Biogen and Eisai’s new candidate drug for Alzheimer’s Disease is showing strong potential in a field…
Interview: Terry O'Regan – Vice President and Managing…
Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues,…
